Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs JNJ 64007957 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 13 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 14 Dec 2019.
    • 08 Nov 2018 Planned End Date changed from 7 Oct 2019 to 1 Jun 2020.
    • 11 Oct 2018 Planned End Date changed from 28 Oct 2020 to 7 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top